New therapies for systemic lupus erythematosus

41Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the past 40 years, prognosis for patients with systemic lupus erythematosus (SLE) has improved, with 10-year survival now approximately 90%. This is due probably to a combination of earlier disease diagnosis and diagnosis of milder disease, due in part to availability of multiple serological tests for SLE, use of steroids and other immunosuppressive agents, and availability of renal dialysis and transplantation. Despite this, however, the potential for significant morbidity and mortality remains in the group of patients with partially responsive or treatment resistant disease. More recently, advancements in the understanding of molecular mechanisms involved in the pathogenesis of SLE have translated to the development of novel therapies, offering possible alternatives to this patient cohort. Discussion of these pharmacological options and ongoing research forms the basis of this review. © 2005 British Society for Immunology.

Cite

CITATION STYLE

APA

Goldblatt, F., & Isenberg, D. A. (2005, May). New therapies for systemic lupus erythematosus. Clinical and Experimental Immunology. https://doi.org/10.1111/j.1365-2249.2005.02795.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free